ATE374777T1 - Analoga als antitumorale verbindungen - Google Patents

Analoga als antitumorale verbindungen

Info

Publication number
ATE374777T1
ATE374777T1 AT02753134T AT02753134T ATE374777T1 AT E374777 T1 ATE374777 T1 AT E374777T1 AT 02753134 T AT02753134 T AT 02753134T AT 02753134 T AT02753134 T AT 02753134T AT E374777 T1 ATE374777 T1 AT E374777T1
Authority
AT
Austria
Prior art keywords
analogue
antitumoral compounds
antitumoral
compounds
ecteinascidin
Prior art date
Application number
AT02753134T
Other languages
English (en)
Inventor
Valentin Martinez
Pilar Gallego
Carmen Cuevas
Simon Munt
Ignacio Manzanares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9919954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE374777(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE374777T1 publication Critical patent/ATE374777T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02753134T 2001-08-07 2002-08-06 Analoga als antitumorale verbindungen ATE374777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743

Publications (1)

Publication Number Publication Date
ATE374777T1 true ATE374777T1 (de) 2007-10-15

Family

ID=9919954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753134T ATE374777T1 (de) 2001-08-07 2002-08-06 Analoga als antitumorale verbindungen

Country Status (22)

Country Link
US (1) US7763615B2 (de)
EP (3) EP1806349A1 (de)
JP (2) JP4684552B2 (de)
KR (1) KR20040032150A (de)
CN (1) CN100334094C (de)
AT (1) ATE374777T1 (de)
AU (1) AU2002313540B2 (de)
CA (1) CA2455768C (de)
CY (1) CY1107830T1 (de)
DE (1) DE60222775T2 (de)
DK (1) DK1414828T3 (de)
ES (1) ES2294151T3 (de)
GB (1) GB0119243D0 (de)
HU (1) HU229779B1 (de)
IL (2) IL160051A0 (de)
MX (1) MXPA04001240A (de)
NO (1) NO337476B1 (de)
NZ (1) NZ530837A (de)
PL (1) PL218295B1 (de)
PT (1) PT1414828E (de)
RU (1) RU2283842C2 (de)
WO (1) WO2003014127A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN103038240A (zh) * 2010-05-25 2013-04-10 法马马有限公司 制备海鞘素化合物的合成方法
RS54648B1 (sr) * 2010-11-12 2016-08-31 Pharma Mar S.A. Kombinovana terapija sa antitumorskim alkaloidom
PL3057323T3 (pl) 2010-11-26 2018-11-30 Nec Corporation Urządzenie do dekodowania wideo, sposób dekodowania wideo oraz program
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
KR102491180B1 (ko) * 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CA3148690A1 (en) 2019-09-03 2021-03-11 Ioannis METAXAS Lurbinectedin in the treatment of malignant mesothelioma
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
PE20252386A1 (es) 2019-11-21 2025-10-10 Pharma Mar Sa Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN115427081B (zh) 2020-04-21 2025-12-09 法马马有限公司 药物抗体共轭物
WO2021218896A1 (zh) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 海鞘素类衍生物及其制备方法与医药用途
AU2020466790B2 (en) 2020-09-04 2025-07-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
IN202141039393A (de) * 2021-08-31 2023-03-03
IL312263A (en) 2021-11-08 2024-06-01 Pharma Mar Sa Lurbinectedin and atezolizumab combinations
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN118388507A (zh) 2022-04-08 2024-07-26 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2024188978A1 (en) 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
WO2025059336A1 (en) * 2023-09-13 2025-03-20 Navinta, Llc An improved process for preparation of lurbinectedin
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (de) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin und eine verwandte verbindung zur verwendung bei der behandlung von hautkrebs
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
EP0309477B1 (de) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ekteinascidine 729, 743, 745, 759a, 759b und 770
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en) 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CA2397597A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
NO337476B1 (no) 2016-04-18
CA2455768A1 (en) 2003-02-20
MXPA04001240A (es) 2004-06-03
RU2283842C2 (ru) 2006-09-20
NZ530837A (en) 2005-07-29
EP1414828B1 (de) 2007-10-03
CA2455768C (en) 2011-10-11
CN1564822A (zh) 2005-01-12
PL367940A1 (en) 2005-03-07
EP1806349A1 (de) 2007-07-11
DE60222775D1 (de) 2007-11-15
IL160051A (en) 2012-01-31
EP1414828A1 (de) 2004-05-06
US20060128711A1 (en) 2006-06-15
HU229779B1 (en) 2014-07-28
DK1414828T3 (da) 2008-02-04
AU2002313540B2 (en) 2008-05-22
CY1107830T1 (el) 2013-06-19
US7763615B2 (en) 2010-07-27
ES2294151T3 (es) 2008-04-01
HUP0401174A3 (en) 2005-12-28
JP2011026331A (ja) 2011-02-10
JP2005501093A (ja) 2005-01-13
PL218295B1 (pl) 2014-11-28
NO20040961L (no) 2004-03-05
EP1414828B9 (de) 2008-02-20
KR20040032150A (ko) 2004-04-14
IL160051A0 (en) 2004-06-20
HK1065786A1 (en) 2005-03-04
EP2270018A1 (de) 2011-01-05
CN100334094C (zh) 2007-08-29
HUP0401174A2 (hu) 2005-09-28
JP4684552B2 (ja) 2011-05-18
DE60222775T2 (de) 2008-07-17
RU2004106617A (ru) 2005-04-10
PT1414828E (pt) 2007-12-27
GB0119243D0 (en) 2001-10-03
WO2003014127A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
DE60222775D1 (de) Analoga als antitumorale verbindungen
NO943002L (no) Fosfono-oksymetyletere av taxanderivater
ATE451349T1 (de) Neue verbindungen als entzündungshemmende, immunmodulierende und antiproliferative mittel
DE69232665D1 (de) Neue 4-arylpiperazine und 4-arylpiperidine
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
ECSP044997A (es) DERIVADOS SUSTITUIDOS DEL INDENO [1,2-c] ISOQUINOLINA
DK0582788T3 (da) 7-(Substituerede)-9-[(substitueret glycyl)-amido]-demethyl-6-deoxytetracycliner
DK1385514T5 (da) Spiroinden- og spiroindanforbindelser
DK1273299T3 (da) Minoxidilinindeholdende praparater
ATE246196T1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
ATE210649T1 (de) Arylacrylamidderivate als 5ht1 agoniste oder antagoniste
MX9702259A (es) Derivados de quinoxalina utiles en terapia.
DK0660822T3 (da) Cykliske benzylamino-, benzylamido- og benzylimidoderivater som antipsykotiske midler
ATE422531T1 (de) Organische verbindungen
ATE469902T1 (de) Amorphe substanz eines tricyclischen triazolobenzazepinderivats
ATE227713T1 (de) 1,2-substituierte 2,3-dihydro-1h-5,9- dioxacyclohepta(f)inden-7-one und 7-substituierte benzo(b)(1,4)dioxepin-3-one
DK0878195T3 (da) Anvendelse af en 2-aroyl-3-arylbenzo(b)thiophenforbindelse til reduktion af fibrinogenniveauerne
DE69434010D1 (de) C7-Taxan-Derivate und diese enthaltende pharmazeutische Zusammenstellungen
ECSP972237A (es) Derivados de 6,5 heterobiciclicos sustituidos
DE69333895D1 (de) Pharmazeutische Zusammensetzungen enthaltend neue iso-Butenyl-substituierte Taxane

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414828

Country of ref document: EP